Products
Moroctocog alfa is commercially available as a lyophilizate (ReFacto). It has been approved in many countries since 2000.
Structure and properties
Moroctocog alfa is a recombinant blood clotting factor VIII produced by biotechnological methods. It is a glycoprotein with 1438 amino acids and a molecular mass of 170 kDa. The B domain has been removed.
Effects
Moroctocog alfa (ATC B02BD02) replaces the missing coagulation factor VIII and enables blood clotting. This prevents the development of bleeding.
Indications
For prevention and treatment of bleeding episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital deficiency of factor VIII).
Dosage
According to the SmPC. The drug is injected intravenously.
Contraindications
- Severe hypersensitivity
For complete precautions, see the drug label.
Interactions
There are no known drug-drug interactions.
Adverse effects
The most common possible adverse effects include the formation of antibodies to factor VIII and vomiting. Rarely, hypersensitivity reactions are possible.